Publications by authors named "Chenou Wang"
Purpose: This study aimed to explore the possibility of utilizing hepatitis B core protein (HBc) virus-like particles (VLPs) encapsulate doxorubicin (Dox) to reduce the adverse effect caused by its off-target and toxic side effect.
Methods: Here, a triple-negative breast cancer (TNBC) tumor-targeting GE11-HBc VLP was constructed through genetic engineering. The GE11 peptide, a 12-amino-acid peptide targeting epidermal growth factor receptor (EGFR), was inserted into the surface protein loops of VLPs.
Background: To date, triple-negative breast cancer (TNBC) treatment options are limited because of the loss of target receptors and, as a result, are only managed with chemotherapy. What is worse is that TNBC is frequently developing resistance to chemotherapy. By using small interfering RNA (siRNA)-based therapeutics, our recent work demonstrated X-box-binding protein 1 (XBP1) was linked to human epidermal growth factor receptor 2 positive (HER2+) breast cancer development and chemoresistance.
View Article and Find Full Text PDFDental implants have great potential in the global market, around $3.7 billion in 2015, which will increase to $7 billion in 2023 with an annual increase rate of 8.2%.
View Article and Find Full Text PDFArticle Synopsis
- Defective SIRT1 expression causes ER stress and cell death in inflammatory bowel disease (IBD), with microRNA-132 (miR-132) repressing SIRT1 and increasing inflammation.
- The study tested catalpol, a potential antioxidant, for its ability to activate SIRT1 and reduce ER stress in a rat model of colitis induced by a chemical agent.
- Results showed that catalpol improved SIRT1 levels, reduced ER stress markers, and alleviated symptoms of colitis, linking the effects of catalpol to the miR-132/SIRT1 pathway in the context of IBD.
Article Synopsis
- Myosin light chain kinase (MLCK) plays a key role in muscle contraction by phosphorylating the myosin light chain, and abnormal MLCK expression is linked to several diseases, including respiratory and cardiovascular disorders, cancer, and inflammatory bowel disease.
- The review discusses signaling pathways that activate MLCK and how this activation can lead to dysfunction in the endothelial barrier, which is crucial for maintaining proper tissue function.
- It also explores the potential benefits of using anti-MLCK agents in treating inflammatory diseases, while highlighting the need to consider possible side effects due to MLCK's widespread presence in various tissues.